<DOC>
	<DOCNO>NCT00482248</DOCNO>
	<brief_summary>This study ass safety tolerability long-term treatment omalizumab extend omalizumab treatment 1 year patient allergic asthma successfully complete study CIGE25011E2 .</brief_summary>
	<brief_title>Safety Tolerability Omalizumab Adults Adolescents With Severe Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients history severe allergic asthma complete treatment period CIGE250011E3 protocol , without experience significant drugrelated adverse event Male female patient 1275 year age give write informed consent approve ethical committee Patients receive study medication great 84 day since visit 38 study CIGE240011E3 Pregnant females nurse mother Patients know hypersensitivity ingredient Omalizumab relate drug Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>anti-immunoglobulin E</keyword>
	<keyword>omalizumab</keyword>
	<keyword>allergic asthma</keyword>
</DOC>